Literature DB >> 23895822

Risk for recurrent coronary heart disease and all-cause mortality among individuals with chronic kidney disease compared with diabetes mellitus, metabolic syndrome, and cigarette smokers.

Usman Baber1, Orlando M Gutierrez, Emily B Levitan, David G Warnock, Michael E Farkouh, Marcello Tonelli, Monika M Safford, Paul Muntner.   

Abstract

BACKGROUND: Lipid-lowering guidelines endorse a low-density lipoprotein cholesterol goal of <100 mg/dL for people with coronary heart disease (CHD). A more stringent threshold of <70 mg/dL is recommended for those with CHD and "very high-risk" conditions such as diabetes mellitus, metabolic syndrome, or cigarette smoking. Whether chronic kidney disease (CKD) confers a similar risk for recurrent CHD events is unknown. METHODS AND
RESULTS: We evaluated the risk for recurrent CHD events and all-cause mortality among 3,938 participants ≥45 years with CHD in the Reasons for Geographic and Racial Differences in Stroke (REGARDS) study. Chronic kidney disease was defined by estimated glomerular filtration rate <60 mL/min per 1.73 m(2) or urinary albumin to creatinine ratio ≥30 mg/g. Participants were categorized by the presence or absence of CKD and any very high-risk condition. Over a median of 4.1 years, the crude incidence (95% CI) of recurrent CHD events were 12.1 (9.0-15.2), 18.9 (15.5-22.3), 35.0 (25.4-44.6), and 34.2 (28.2-40.3) among those without CKD or high-risk conditions; very high-risk conditions alone; and CKD alone and both CKD and very high-risk conditions. After multivariable adjustment, compared with those without CKD or very high-risk conditions, the hazard ratio (95% CI) for recurrent CHD events was 1.45 (1.02-2.05), 2.24 (1.50-3.34), and 2.10 (1.47-2.98) among those with very high-risk conditions alone, CKD alone, and both CKD and very high-risk conditions, respectively. Results were consistent for all-cause mortality.
CONCLUSIONS: Chronic kidney disease is associated with risk for recurrent CHD events that approximates or is larger than other established very high-risk conditions.
Copyright © 2013 Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Year:  2013        PMID: 23895822      PMCID: PMC4139360          DOI: 10.1016/j.ahj.2013.05.008

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  15 in total

1.  AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients with Coronary and other Atherosclerotic Vascular Disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation.

Authors:  Sidney C Smith; Emelia J Benjamin; Robert O Bonow; Lynne T Braun; Mark A Creager; Barry A Franklin; Raymond J Gibbons; Scott M Grundy; Loren F Hiratzka; Daniel W Jones; Donald M Lloyd-Jones; Margo Minissian; Lori Mosca; Eric D Peterson; Ralph L Sacco; John Spertus; James H Stein; Kathryn A Taubert
Journal:  Circulation       Date:  2011-11-03       Impact factor: 29.690

2.  The reasons for geographic and racial differences in stroke study: objectives and design.

Authors:  Virginia J Howard; Mary Cushman; Leavonne Pulley; Camilo R Gomez; Rodney C Go; Ronald J Prineas; Andra Graham; Claudia S Moy; George Howard
Journal:  Neuroepidemiology       Date:  2005-06-29       Impact factor: 3.282

3.  Risk of coronary events in people with chronic kidney disease compared with those with diabetes: a population-level cohort study.

Authors:  Marcello Tonelli; Paul Muntner; Anita Lloyd; Braden J Manns; Scott Klarenbach; Neesh Pannu; Matthew T James; Brenda R Hemmelgarn
Journal:  Lancet       Date:  2012-06-19       Impact factor: 79.321

4.  Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels.

Authors: 
Journal:  N Engl J Med       Date:  1998-11-05       Impact factor: 91.245

5.  National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification.

Authors:  Andrew S Levey; Josef Coresh; Ethan Balk; Annamaria T Kausz; Adeera Levin; Michael W Steffes; Ronald J Hogg; Ronald D Perrone; Joseph Lau; Garabed Eknoyan
Journal:  Ann Intern Med       Date:  2003-07-15       Impact factor: 25.391

6.  Use of evidence-based therapies in short-term outcomes of ST-segment elevation myocardial infarction and non-ST-segment elevation myocardial infarction in patients with chronic kidney disease: a report from the National Cardiovascular Data Acute Coronary Treatment and Intervention Outcomes Network registry.

Authors:  Caroline S Fox; Paul Muntner; Anita Y Chen; Karen P Alexander; Matthew T Roe; Christopher P Cannon; Jorge F Saucedo; Michael C Kontos; Stephen D Wiviott
Journal:  Circulation       Date:  2010-01-11       Impact factor: 29.690

7.  The case for chronic kidney disease, diabetes mellitus, and myocardial infarction being equivalent risk factors for cardiovascular mortality in patients older than 65 years.

Authors:  Arash Rashidi; Ashwini Reddi Sehgal; Mahboob Rahman; Andrew Stenson O'Connor
Journal:  Am J Cardiol       Date:  2008-10-23       Impact factor: 2.778

8.  Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity.

Authors:  K G M M Alberti; Robert H Eckel; Scott M Grundy; Paul Z Zimmet; James I Cleeman; Karen A Donato; Jean-Charles Fruchart; W Philip T James; Catherine M Loria; Sidney C Smith
Journal:  Circulation       Date:  2009-10-05       Impact factor: 29.690

9.  A new equation to estimate glomerular filtration rate.

Authors:  Andrew S Levey; Lesley A Stevens; Christopher H Schmid; Yaping Lucy Zhang; Alejandro F Castro; Harold I Feldman; John W Kusek; Paul Eggers; Frederick Van Lente; Tom Greene; Josef Coresh
Journal:  Ann Intern Med       Date:  2009-05-05       Impact factor: 25.391

10.  The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial.

Authors:  Colin Baigent; Martin J Landray; Christina Reith; Jonathan Emberson; David C Wheeler; Charles Tomson; Christoph Wanner; Vera Krane; Alan Cass; Jonathan Craig; Bruce Neal; Lixin Jiang; Lai Seong Hooi; Adeera Levin; Lawrence Agodoa; Mike Gaziano; Bertram Kasiske; Robert Walker; Ziad A Massy; Bo Feldt-Rasmussen; Udom Krairittichai; Vuddidhej Ophascharoensuk; Bengt Fellström; Hallvard Holdaas; Vladimir Tesar; Andrzej Wiecek; Diederick Grobbee; Dick de Zeeuw; Carola Grönhagen-Riska; Tanaji Dasgupta; David Lewis; William Herrington; Marion Mafham; William Majoni; Karl Wallendszus; Richard Grimm; Terje Pedersen; Jonathan Tobert; Jane Armitage; Alex Baxter; Christopher Bray; Yiping Chen; Zhengming Chen; Michael Hill; Carol Knott; Sarah Parish; David Simpson; Peter Sleight; Alan Young; Rory Collins
Journal:  Lancet       Date:  2011-06-12       Impact factor: 79.321

View more
  17 in total

Review 1.  Chronic kidney disease induced dysfunction of high density lipoprotein.

Authors:  Suguru Yamamoto; Valentina Kon
Journal:  Clin Exp Nephrol       Date:  2013-09-10       Impact factor: 2.801

2.  Race, ethnicity, and state-by-state geographic variation in hemorrhagic stroke in dialysis patients.

Authors:  James B Wetmore; Milind A Phadnis; Jonathan D Mahnken; Edward F Ellerbeck; Sally K Rigler; Xinhua Zhou; Theresa I Shireman
Journal:  Clin J Am Soc Nephrol       Date:  2014-01-23       Impact factor: 8.237

Review 3.  Coronary heart disease risk factors and outcomes in the twenty-first century: findings from the REasons for Geographic and Racial Differences in Stroke (REGARDS) Study.

Authors:  Hemal Bhatt; Monika Safford; Stephen Glasser
Journal:  Curr Hypertens Rep       Date:  2015-04       Impact factor: 5.369

Review 4.  Heart Disease and Stroke Statistics-2017 Update: A Report From the American Heart Association.

Authors:  Emelia J Benjamin; Michael J Blaha; Stephanie E Chiuve; Mary Cushman; Sandeep R Das; Rajat Deo; Sarah D de Ferranti; James Floyd; Myriam Fornage; Cathleen Gillespie; Carmen R Isasi; Monik C Jiménez; Lori Chaffin Jordan; Suzanne E Judd; Daniel Lackland; Judith H Lichtman; Lynda Lisabeth; Simin Liu; Chris T Longenecker; Rachel H Mackey; Kunihiro Matsushita; Dariush Mozaffarian; Michael E Mussolino; Khurram Nasir; Robert W Neumar; Latha Palaniappan; Dilip K Pandey; Ravi R Thiagarajan; Mathew J Reeves; Matthew Ritchey; Carlos J Rodriguez; Gregory A Roth; Wayne D Rosamond; Comilla Sasson; Amytis Towfighi; Connie W Tsao; Melanie B Turner; Salim S Virani; Jenifer H Voeks; Joshua Z Willey; John T Wilkins; Jason Hy Wu; Heather M Alger; Sally S Wong; Paul Muntner
Journal:  Circulation       Date:  2017-01-25       Impact factor: 29.690

Review 5.  αKlotho and vascular calcification: an evolving paradigm.

Authors:  Ming Chang Hu; Makoto Kuro-o; Orson W Moe
Journal:  Curr Opin Nephrol Hypertens       Date:  2014-07       Impact factor: 2.894

6.  Elderly patients with chronic kidney disease have higher risk of hyperparathyroidism.

Authors:  Rosilene M Elias; Rosa M A Moysés
Journal:  Int Urol Nephrol       Date:  2017-07-10       Impact factor: 2.370

Review 7.  The Kidney-Vascular-Bone Axis in the Chronic Kidney Disease-Mineral Bone Disorder.

Authors:  Michael E Seifert; Keith A Hruska
Journal:  Transplantation       Date:  2016-03       Impact factor: 4.939

8.  Adiponectin and visfatin may serve as diagnosis markers for metabolic syndrome in Uygur population.

Authors:  Xi Chang; Yi Jiao; Jianfei Lu; Yanjiao Wang; Kelim Abudureyimu; Cheng Zhang; Nuerbiye Nuermaimaiti; Xian Gong; Yiliyasi Aisa; Yaqun Guan
Journal:  Int J Clin Exp Med       Date:  2014-11-15

9.  Left ventricular mass progression despite stable blood pressure and kidney function in stage 3 chronic kidney disease.

Authors:  Michael E Seifert; Lisa de Las Fuentes; Charles Ginsberg; Marcos Rothstein; Dennis J Dietzen; Steven C Cheng; Will Ross; David Windus; Victor G Dávila-Román; Keith A Hruska
Journal:  Am J Nephrol       Date:  2014-05-06       Impact factor: 3.754

10.  Incidence and impact on prognosis of bleeding during percutaneous coronary interventions in patients with chronic kidney disease.

Authors:  Gjin Ndrepepa; Franz-Josef Neumann; Salvatore Cassese; Massimiliano Fusaro; Ilka Ott; Stefanie Schulz; Petra Hoppmann; Gert Richardt; Karl-Ludwig Laugwitz; Heribert Schunkert; Adnan Kastrati
Journal:  Clin Res Cardiol       Date:  2013-10-04       Impact factor: 5.460

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.